Risk–Benefit Profile of Oral Antiplatelet Strategies After Percutaneous Coronary Intervention with a Drug-eluting Stent: A Contemporary Network Meta-analysis of Major Bleeding and Stent Thrombosis Outcomes
4 affiliations
- 1Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Jember – Dr Soebandi General Hospital Jember, Indonesia
- 2Faculty of Medicine, Universitas Jember Jember, Indonesia
- 3Department of Epidemiology and Preventive Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University Kagoshima, Japan
- 4Kalisat General Hospital Jember, Indonesia
Abstract
Background:: Optimal antiplatelet therapy after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) requires balancing thrombotic protection and bleeding risk, but the comparative effectiveness of current strategies remains uncertain.
Aims:: To evaluate the risk–benefit profile of oral antiplatelet strategies after PCI with DES, focusing on major bleeding and stent thrombosis.
Methods:: A network meta-analysis of randomised and observational studies was conducted. Strategies included standard or extended dual antiplatelet therapy (DAPT), shortened DAPT followed by monotherapy and P2Y12 inhibitor-based monotherapy. Outcomes were analysed using a random-effects model and ranked with p-scores. Evidence certainty was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE).
Results:: Thirty studies involving 110,035 patients were included. Ticagrelor monotherapy ranked highest for reducing major bleeding, whereas extended DAPT provided the greatest protection against stent thrombosis, with clopidogrel-based therapy beyond 12 months ranking highest (RR 0.08; 95% CI [0.01–0.52]; p-score=0.94). Notably, clopidogrel monotherapy after prolonged DAPT demonstrated a relatively balanced profile across both outcomes. However, no strategy was consistently optimal and most estimates showed wide CIs.
Conclusion:: Antiplatelet strategies after PCI with DES involve a clear trade-off between bleeding and thrombotic risk. Clopidogrel monotherapy after prolonged DAPT may offer a balanced approach, although findings should be interpreted cautiously due to limited precision and consistency.
Related
- Antiplatelet Therapy Strategies in Patients with High Bleeding Risk Treated with Complex Percutaneous Coronary Intervention: A Descriptive Study
- Dual antiplatelet therapy duration after percutaneous coronary intervention with contemporary drug-eluting stents: A systematic review and network meta-analysis of randomized trials
- Antiplatelet monotherapy maintenance strategies after percutaneous coronary intervention in patients with coronary artery disease at high bleeding risk: a network meta-analysis
- Spontaneous Spinal Epidural Hematoma: An Urgent Complication of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Non-ST-elevation Myocardial Infarction
- Contemporary sirolimus-based stent platforms versus durable-polymer limus-eluting stents in patients with diabetes undergoing percutaneous coronary intervention: a systematic review and meta-analysis
BibTeX
@article{suryono2026riskbenefit,
title = {{Risk–Benefit Profile of Oral Antiplatelet Strategies After Percutaneous Coronary Intervention with a Drug-eluting Stent: A Contemporary Network Meta-analysis of Major Bleeding and Stent Thrombosis Outcomes}},
author = {Suryono Suryono and Muhammad Farhan Hibatulloh and Alfiyah Ramadhani and Candra Agung Wibisana and Muhammad Naufal Hibatullah and Achmad Ilham Tohari and Muhammad Rijal Fahrudin Hidayat and Muhammad Irsyad Amien and Hazbina Fauqi Ramadhan},
journal = {European Cardiology Review},
year = {2026},
month = oct,
doi = {10.15420/ecr.2026.29},
url = {https://doi.org/10.15420/ecr.2026.29},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Risk–Benefit Profile of Oral Antiplatelet Strategies After Percutaneous Coronary Intervention with a Drug-eluting Stent: A Contemporary Network Meta-analysis of Major Bleeding and Stent Thrombosis Outcomes
AU - Suryono Suryono
AU - Muhammad Farhan Hibatulloh
AU - Alfiyah Ramadhani
AU - Candra Agung Wibisana
AU - Muhammad Naufal Hibatullah
AU - Achmad Ilham Tohari
AU - Muhammad Rijal Fahrudin Hidayat
AU - Muhammad Irsyad Amien
AU - Hazbina Fauqi Ramadhan
PY - 2026
DA - 2026/10/30
JO - European Cardiology Review
DO - 10.15420/ecr.2026.29
UR - https://doi.org/10.15420/ecr.2026.29
AB - Background:: Optimal antiplatelet therapy after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) requires balancing thrombotic protection and bleeding risk, but the comparative effectiveness of current strategies remains uncertain. Aims:: To evaluate the risk–benefit profile of oral antiplatelet strategies after PCI with DES, focusing on major bleeding and stent thrombosis. Methods:: A network meta-analysis of randomised and observational studies was conducted. Strategies included standard or extended dual antiplatelet therapy (DAPT), shortened DAPT followed by monotherapy and P2Y12 inhibitor-based monotherapy. Outcomes were analysed using a random-effects model and ranked with p-scores. Evidence certainty was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE). Results:: Thirty studies involving 110,035 patients were included. Ticagrelor monotherapy ranked highest for reducing major bleeding, whereas extended DAPT provided the greatest protection against stent thrombosis, with clopidogrel-based therapy beyond 12 months ranking highest (RR 0.08; 95% CI [0.01–0.52]; p-score=0.94). Notably, clopidogrel monotherapy after prolonged DAPT demonstrated a relatively balanced profile across both outcomes. However, no strategy was consistently optimal and most estimates showed wide CIs. Conclusion:: Antiplatelet strategies after PCI with DES involve a clear trade-off between bleeding and thrombotic risk. Clopidogrel monotherapy after prolonged DAPT may offer a balanced approach, although findings should be interpreted cautiously due to limited precision and consistency.
SN - 1758-3756
SN - 1758-3764
ER -